- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04706130
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be an open-labelled randomized clinical trial to determine therapeutic efficacy. Note that this will not be an Investigational New Drug application, as only World Health Organization-approved drugs will be used at dosage and for conditions approved.
Eligible patients willing to participate will first be tested prior to enrolment for their glucose-6-phosphate dehydrogenase (G6PD) status by the gold standard spectrophotometric analysis. The investigators will exclude from the study any G6PD deficient (or intermediate females) patient. Treatment allocation will be randomized between i) 7 days of artesunate (2 mg/kg/day for 7 days) alone (Arm1), ii) same artesunate regimen + 0.25 mg/kg/day 14 days of primaquine (Arm2) and iii) same artesunate regimen + 0.5 mg/kg/day 14 days of primaquine (Arm3). All patients will be relocated to a no-transmission city to make sure they are not reinfected during the follow-up. Follow-up will be performed every 24-48h for 90 days. At the end of the follow-up period, all patients that did not receive primaquine (arm1) will be treated according to national guidelines (14 days at 0.25mg/kg/day). Patients will additionally be followed monthly for three months after the end of the relocation.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Phnom Penh, Cambodia
- Recruiting
- Institut Pasteur du Cambodge
-
Contact:
- Jean Popovici, Ph.D.
- Phone Number: 089 851 806
- Email: jpopovici@pasteur-kh.org
-
Principal Investigator:
- Jean Popovici, PhD
-
Principal Investigator:
- Benoit Witkowski, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 15 and older
- Acute (within 10 days), symptomatic (i.e., history of fever), uncomplicated malaria caused solely by Plasmodium vivax (verified by PCR)
- G6PD normal (as determined by quantitative spectrophotometric assay)
Exclusion Criteria:
- Pregnant, planning to become pregnant or lactating women,
- Received antimalarial drugs in the past month,
- Hb < 8g/dL, < 1,500 neutrophils/μl, or signs of complicated malaria (e.g., vomiting, convulsions,…),
- History of primaquine, artesunate or artesunate-mefloquine allergy or intolerance,
- PCR-positivity for severe acute respiratory syndrome coronavirus 2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Arm1: No primaquine
Enrolled patients will only received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days)
|
All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
|
Other: Arm2: Primaquine low dose
Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.25 mg/kg/day for 14 days (starting at day 7)
|
All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
|
Other: Arm3: Primaquine high dose
Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.50 mg/kg/day for 14 days (starting at day 7)
|
All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
P. vivax recurrence
Time Frame: 3 months
|
Proportion of patients experiencing recurrence as measured by microscopy and PCR and time to recurrence
|
3 months
|
Markers of P. vivax recurrences
Time Frame: 3 months
|
Gene expression or serological markers associated with P. vivax recurrence
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Genotypes of relapsing P. vivax parasites
Time Frame: 3 months
|
Genotypes of relapsing P. vivax parasites
|
3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Mosquito-Borne Diseases
- Malaria, Vivax
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Primaquine
- Artesunate
Other Study ID Numbers
- 20-0010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vivax Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
Centers for Disease Control and PreventionTerminated
-
Menzies School of Health ResearchMinistry of Health, MalaysiaUnknownPlasmodium Vivax Malaria Without ComplicationMalaysia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... and other collaboratorsRecruitingVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Malaria RelapseCambodia, Ethiopia, Indonesia, Pakistan
-
Menzies School of Health ResearchUniversity of Melbourne; Curtin University; Addis Ababa University; Fundação de... and other collaboratorsNot yet recruitingVivax MalariaBrazil, Ethiopia, Indonesia, Papua New Guinea
-
University of OxfordCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompletedMalaria | Vivax MalariaPakistan
Clinical Trials on Artesunate
-
PfizerCompletedFalciparum MalariaSingapore
-
University of OxfordMahidol University; Worldwide Antimalarial Resistance NetworkCompletedFalciparum MalariaKenya, Thailand, Cambodia, Bangladesh, Congo, The Democratic Republic of the, India, Lao People's Democratic Republic, Myanmar, Nigeria, Vietnam
-
Medicines for Malaria VentureShin Poong PharmaceuticalsCompletedFalciparum MalariaCambodia, India, Thailand, Burkina Faso, Côte D'Ivoire, Tanzania, Vietnam
-
University of OxfordKinshasa School of Public HealthCompletedMalariaCongo, The Democratic Republic of the
-
Medicines for Malaria VentureShin Poong Pharmaceutical Co. Ltd.CompletedMalariaKorea, Republic of
-
London School of Hygiene and Tropical MedicineKintampo Health Research Centre, GhanaCompleted
-
Shin Poong Pharmaceutical Co. Ltd.Recruiting
-
University of OxfordShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; National Institute... and other collaboratorsCompletedSevere MalariaCongo, The Democratic Republic of the
-
Heidelberg UniversityCompleted